Chronic Hepatitis B Patient Cohort with HCC Risk Factors, 2004-2022

A cohort of 1012 chronic hepatitis B patients treated with nucleos(t)ide analogs between 2004 and 2022, with a 5.5-year follow-up period. The dataset, authored by Hung-Wei Wang and shared on figshare, includes patient stratification by steatotic liver disease and cardiometabolic risk factors, tracking 73 incident hepatocellular carcinoma cases. It explores the modifying roles of metabolic profiles on HCC risk during antiviral therapy.

Use Cases

• Modeling hepatocellular carcinoma risk based on the presence or absence of steatotic liver disease.
• Analyzing the impact of cardiometabolic burden on cancer incidence in treated chronic hepatitis B patients.
• Studying the interaction between metabolic dysregulation and antiviral treatment outcomes.
• Validating precision risk stratification frameworks that incorporate steatosis and metabolic factors.

Strengths

• 1012 patient records from a longitudinal study spanning 18 years (2004-2022).
• Includes a 5.5-year follow-up period with 73 documented hepatocellular carcinoma events.
• Patient groups are clearly stratified (SLD N=702, non-SLD N=310) with baseline characteristics described.
• Analysis includes adjusted hazard ratios for key risk factors (e.g., SLD: 0.43, ≥2 CMRFs: 1.93).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying data tables is unknown, which may limit suitability assessment.
• The dataset's 25.1 MB size suggests it is a small-scale clinical study.

Provenance

Source

figshare, author Hung-Wei Wang.

Collection Method

Clinical cohort study of patients receiving nucleos(t)ide analog treatment.

Time Range

2004 to 2022, with a 5.5-year follow-up period.

Freshness

Last updated 2026-04-20 09:20:05; freshness should be verified.